MetaCap

Mirum Pharmaceuticals (MIRM) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Supernus (SUPN) over the past year, gaining 35.5% versus a loss of 36.9%. Over five years, MIRM leads with a +616.9% price change compared with -6.5% for SUPN. Mirum Pharmaceuticals is the larger company by market cap ($6.28 billion vs $5.94 billion), about 1.1 times the size.

On valuation, Supernus trades at a lower forward P/E (7.1x vs 300.4x for Mirum Pharmaceuticals). Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -5.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIRM+35.45%SUPN-36.87%
+87%+19%-48%
Nov 21, 20251 yearNov 20, 2026
MIRM+512.68%SUPN-14.52%
+737%+335%-66%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIRM versus SUPN key metrics
MetricMIRMSUPN
Share price$96.13$28.61
Market cap$6.28B$5.94B
1-day change+0.65%+0.92%
YTD return+21.70%-42.43%
1-year return+35.45%-36.87%
5-year return+616.85%-6.53%
Forward P/E300.417.15
EPS (TTM)$-14.47$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$521.31M$718.95M
Revenue growth (YoY)+54.74%+8.63%
Net income (latest FY)$-23.36M$-38.55M
Gross margin—89.63%
Operating margin-4.25%-8.66%
Net margin-4.48%-5.36%
52-week high$130.00$42.81
52-week low$63.23$25.92
Distance from 52-week high-26.05%-33.17%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+64.06%+89.23%
Average volume692.51K2.77M
Shares outstanding65.28M207.72M
Employees470827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed SUPN by 72.3 percentage points over the past year.
  • Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs +8.63%).

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

MIRM vs SUPN FAQ

Which is bigger, Mirum Pharmaceuticals or Supernus?

Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $6.28B compared with $5.94B for Supernus (SUPN).

Which stock has performed better over the past year, MIRM or SUPN?

MIRM returned +35.45% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.

Are Mirum Pharmaceuticals and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons